CRDL
HEALTHCARECardiol Therapeutics Inc - Class A
$1.32+0.01 (+0.76%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CRDL Today?
No stock-specific AI insight has been generated for CRDL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.88$1.71
$1.32
Fundamentals
Market Cap$147M
P/E Ratio—
EPS$-0.29
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin—
Debt / Equity—
Trading
Volume386K
Avg Volume (10D)—
Shares Outstanding111.7M
CRDL News
20 articles- Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart AssociationYahoo Finance·May 7, 2026
- Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.Yahoo Finance·Apr 28, 2026
- Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal ProgramYahoo Finance·Apr 28, 2026
- Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis PromiseMarketbeat·Apr 15, 2026
- Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartYahoo Finance·Apr 14, 2026
- Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trialYahoo Finance·Apr 1, 2026
- Cardiol Therapeutics Announces Year-End 2025 Update on OperationsYahoo Finance·Apr 1, 2026
- Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare ConferenceMarketbeat·Mar 8, 2026
- Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?Yahoo Finance·Mar 3, 2026
- Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart FailureYahoo Finance·Feb 10, 2026
- Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 MillionYahoo Finance·Jan 23, 2026
- Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 MillionYahoo Finance·Jan 16, 2026
- Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 MillionYahoo Finance·Jan 16, 2026
- Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent PericarditisYahoo Finance·Jan 13, 2026
- Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before LongYahoo Finance·Jan 12, 2026
- New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac ConditionsYahoo Finance·Dec 1, 2025
- Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040Yahoo Finance·Nov 13, 2025
- Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial DiseasesYahoo Finance·Nov 5, 2025
- TSX Penny Stocks To Watch In October 2025Yahoo Finance·Oct 21, 2025
All 20 articles loaded
Price Data
Open$1.32
Previous Close$1.31
Day High$1.36
Day Low$1.28
52 Week High$1.71
52 Week Low$0.88
52-Week Range
$0.88$1.71
$1.32
Fundamentals
Market Cap$147M
P/E Ratio—
EPS$-0.29
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin—
Debt / Equity—
Trading
Volume386K
Avg Volume (10D)—
Shares Outstanding111.7M
About Cardiol Therapeutics Inc - Class A
Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—